<DOC>
	<DOCNO>NCT01759264</DOCNO>
	<brief_summary>The objective observational study ass change fecal calprotectin level suitability monitoring tool participant moderate-to-severe Crohn 's Disease treat adalimumab .</brief_summary>
	<brief_title>An Observational Study Fecal Calprotectin Clinical Tool Monitoring Moderate-to-severe Crohn 's Disease Adalimumab Induction Therapy : KoRean Experience ( FAIR )</brief_title>
	<detailed_description />
	<mesh_term>Crohn Disease</mesh_term>
	<mesh_term>Adalimumab</mesh_term>
	<criteria>1 . Crohn 's Disease participant define : 1 . Active luminal , moderatetosevere Crohn 's Disease Crohn 's disease activity index ( CDAI ) great 220 , start Adalimumab treatment normal clinical practice set . 2 . Fecal Calprotectin great equal 150 microgram/g . 3 . Ileocolonic colonic disease , without involvement proximal gastrointestinal area . 1 . Disease restrict proximal ( small bowel , gastroduodenal ) gastrointestinal tract . 2 . Participants undergone colectomy ileocecal resection . 3 . Pregnancy breast feed . 4 . Contraindication antitumor necrosis factor ( TNF ) agent . 5 . Any drug dependency .</criteria>
	<gender>All</gender>
	<minimum_age>19 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2015</verification_date>
	<keyword>Fecal Calprotectin</keyword>
	<keyword>Crohn 's Disease</keyword>
	<keyword>Adalimumab</keyword>
</DOC>